louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03734822: Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
Official title: Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2018-11-08
Enrollment: 47
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Four methods are routinely used to monitor CO2 in patients. End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia. CO2 is also monitored in other healthcare settings transcutaneously (TCO2), via finger stick capillary CO2 (CapCO2), and arterial blood gas (ABG). The purpose of this study is to perform all four measurements simultaneously during general anesthesia to identify which measure provides the most accurate data with the least amount of patient risk.


Eligibility criteria: Inclusion Criteria:

* Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
* Hemodynamically stable undergoing general anesthesia for a scheduled procedure

Exclusion Criteria:

* Patients not diagnosed with CF
* CF patients undergoing anesthesia for emergency procedures

Primary outcomes:
measure: Accuracy of CO2 Levels
timeFrame: Immediately following induction of anesthesia
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT06457022: Outcome Measures of Modified Constraint Induced Movement Therapy Versus Dual Task Training on Upper Extremity and Cognitive Functions in Patients With Hemiparesis
Official title: Outcome Measures of Modified Constraint Induced Movement Therapy Versus Dual Task Training on Upper Extremity and Cognitive Functions in Patients With Hemiparesis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiparesis
Keywords: Modified constraint induced movement therapy
Hemiparesis
Dual task training
Upper extremity
Cognitive functions
Lead sponsor: AlRyada University for Science & Technology
Sponsor class: OTHER
First posted: 2024-06-13
Enrollment: 45
Sex: ALL
Minimum age (years): 55
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: All stroke patients were assessed via isokinetic dynamometer, Montreal cognitive assessment scale (MOCA) and Fugl Myer Upper extremity (FMUE) before and after the treatment program.

Detailed description: The patients were classified randomly into three equal groups, Study group A (GA) receiving modified constraint induced movement therapy in addition to conventional physical therapy program, Study group B (GB) receiving dual task training in addition to conventional physical therapy program and control group C (GC) receiving only conventional physiotherapy program.

Eligibility criteria: Inclusion Criteria:

* Patients with age range between 55 and 65 years old.
* The patients were from both genders (males \&females).
* Patients were of duration of illness between 6 and 12 months.
* The patients were scoring 1 \&1+ on modified Ashworth scale (mild spasticity).
* The patients were of good ability to see and hear.
* Consent form was obtained from all participants to approve the study and follow the commands.
* All patients were scoring more than 26 on MMSE. All patients were medically stable.

Exclusion Criteria:

* patients with moderate and sever spasticity.
* patients with cognitive disorder due to other cause rather than spasticity.
* patients with unstable medical conditions.
* patients with previous or recurrent stroke.
* patients with respiratory problems.
* patients with shoulder dislocation or subluxation or frozen shoulder.
* patients with uncontrolled hypertension, diabetes mellitus, unstable angina or heart failure.

Primary outcomes:
measure: Biodex isokinetic dynamometer
timeFrame: 4 weeks
measure: Montreal cognitive assessment
timeFrame: 4 weeks
measure: Fugl Myer upper extremity
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sadat
country: Egypt
facility: Al Ryada University for Science and Technology
state: Menoufia
Study officials:
References:
Clinical trial NCT03793322: The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
Official title: The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular Carcinoma
Indocyanine-Green(ICG)
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2019-01-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to evaluate the feasibility of indocyanine green (ICG)-based fluorescence imaging in the detection of liver tumors. By correlating the ICG fluorescence patterns with pathologically confirmed tumors , it would be possible to use fluorescence navigation system in helping promoting oncology treatment.


Eligibility criteria: Inclusion Criteria:

* 18 years≤ Age ≤70 years
* Compling with the diagnosis criteria of hepatic carcinoma.
* Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled.
* Preoperative liver function is Child - Pugh grade A or B.
* The patients are volunteered for the study.

Exclusion Criteria:

* Patients with mental illness.
* Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.
* The patients refused to take part in the study.
* There are other co-existed malignant tumors.
* Benign liver diseases.
* Indocyanine green allergy

Primary outcomes:
measure: The accuracy of detecting small liver tumor by ICG fluorescence.
timeFrame: 3 Days
measure: The accuracy of positive margins of resection detected by ICG fluorescence.
timeFrame: 3 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang Hospital of Southern Medical University
state: Guangdong
Study officials:
affiliation: China, Guangdong Zhujiang Hospital of The Southern Medical University
name: Chihua Fang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00817622: Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM
Official title: Effects of EPA Alone and Combined With Vitamin E on Blood Leptin, Adiponectin and Enzymatic Antioxidants Levels in Type II Diabetic Patients; A Randomized, Double-Blind, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus
Keywords: diabetes mellitus type 2
EPA
leptin
adiponectin
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-01-06
Enrollment: 129
Sex: ALL
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate efficacy and safety of EPA(Eicosapentaenoic Acid)alone and with VitE in diabetic patients.

Detailed description: Randomized, double-blind, placebo-controlled, parallel-group study design After a 12weeks, subjects with type II DM will be randomized to receive either 2000 mg pearl EPA per day plus a double-blinded matching placebo (1 corn oil pearls per day) for 12 weeks OR 400 mg VitE pearl plus double-blinded per day plus a double-blinded matching placebo (4 corn oil pearls per day) for 12 weeks OR 2000 mg pearl EPA per day plus a double-blinded matching 400 mg VitE pearl OR placebo(4corn oil pearls per day plus 1 corn oil pearls per day )for 12 weeks.The total dose of EPA pearl will be 2000 mg per day (with the EPA or matching placebo corn oil doses remaining at 4 pearls per day) and The total dose of VitE pearl will be 400 mg per day (with the VitE or matching placebo corn oil doses remaining at 1 pearls per day).

Eligibility criteria: Inclusion Criteria:

* DM Type II.
* Antidiabetic drug therapy which cannot be stopped.
* History of DM about 2-15 year.
* Age between 30-55 year.
* No History of circulatory, thyroid, pulmonary, liver, kidney, cancer.

Exclusion Criteria:

* DM Type I.
* Nephropathy.
* Retinopathy.
* Cancer.
* Thyroid disease.
* Renal failure.
* pulmonary disease
* MI.
* CHD.
* Liver disease,

Primary outcomes:
measure: Changes in leptin and adiponectin after 12 Weeks
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Tehran University Of Medical Sciences
Study officials:
affiliation: Tehran University of Medical Sciences, school of Public Health
name: Mahmood Djalali, Professor
role: STUDY_CHAIR
affiliation: Tehran University of Medical Sciences, School of Public Health
name: Shokooh Sarbolouki, PhD Student
role: PRINCIPAL_INVESTIGATOR
affiliation: Tehran University of Medical Sciences,School of Public Health
name: Ahmad Reza - Dorosti, Ph.D.
role: STUDY_CHAIR
References:
citation: Sarbolouki Sh, Djalali M, Dorosty A, Djazayery S, Eshraghian M, Ebadi S, Hashemi S. Effects of EPA and Vitamin E on Serum Enzymatic Antioxidants and Peroxidation Indices in Patients with Type II Diabetes Mellitus. Iran J Public Health. 2010;39(3):82-91. Epub 2010 Sep 30.
Clinical trial NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease
Official title: A Pilot Study to Determine the Safety of Defibrotide in Children With High Risk Kawasaki Disease
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Kawasaki Disease
Keywords: Kawasaki
Children
Defibrotide
Lead sponsor: New York Medical College
Sponsor class: OTHER
Collaborators: name: Johns Hopkins University
name: Columbia University
name: New York University
First posted: 2021-03-02
Enrollment: 2
Sex: ALL
Minimum age (years): 0
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluates the safety of defibrotide with IVIG in children with high risk Kawasaki disease.


Eligibility criteria: Inclusion Criteria:

* Kawasaki disease presumptive diagnosis defined according AHA criteria;
* Signed informed consent and patient assent (if applicable)
* Diagnosis of KD and initiation of defibrotide within 96 hours from the conclusion of IVIG treatment
* Age: 0 - 11 years old
* High risk category defined as patient meeting ≥2 of the following criteria: male, age \<6 months or \>8yrs, IVIG-resistance, Fever lasting greater than 10 days, prior to diagnosis, Coronary artery aneurysms, and/or Laboratory tests indicating worse systemic inflammation
* PT and PTT within institutional normal limits
* Platelet count ≥100,000/mm3

Exclusion Criteria:

* History of Grade III or IV hemorrhage or active bleeding;
* Previous Grade II-IV hypersensitivity to defibrotide
* Current systemic anti-coagulant therapy and/or fibrinolytic therapy, excluding aspirin (5 mg/kg/dose maximum).
* Patients on an active experimental trial for Kawasaki disease

Primary outcomes:
measure: Number of patients with grade III/IV allergic reaction to defibrotide
timeFrame: 30 days
measure: Number of patients with grade III/IV hemorrhage attributable to defibrotide
timeFrame: 42 days
Secondary outcomes:
measure: Number of patients with improvement in clinical progression/signs of Kawasaki disease
timeFrame: 42 days
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University
state: New York
city: New York
country: United States
facility: New York University
state: New York
city: Valhalla
country: United States
facility: Mitchell Cairo
state: New York
Study officials:
affiliation: New York Medical College
name: Mitchell S. Cairo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04049422: Pulmonary Nodule Cohort
Official title: Pulmonary Nodule Cohort
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pulmonary Nodule, Solitary
Lung Cancer
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2019-08-08
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with pulmonary nodule(s) for which lung cancer is suspected

Brief summary: The aim of this study is to identify the clinical features of pulmonary nodules and establish a cohort to identify biomarkers for lung cancer.


Eligibility criteria: Inclusion Criteria:

* age \>= 18
* pulmonary nodule(s) on chest CT, which satisfy at least one of the following two criteria,

  * 4A or above in Lung-RADS v1.1
  * lung cancer risk \>= 5% in Brock model

Exclusion Criteria:

* already proven lung cancer

Primary outcomes:
measure: Incidence of lung cancer
timeFrame: up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01019122: Longitudinal Assessment of Bone Growth in Children With Cerebral Palsy
Official title: Longitudinal Assessment of Bone Growth and Development in a Facility-Based Population of Children With Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Palsy
Bone Density
Keywords: cerebral palsy
DEXA scan
bone density
Lead sponsor: Akron Children's Hospital
Sponsor class: OTHER
Collaborators: name: Kent State University
name: University of North Carolina
name: Alfred I. duPont Hospital for Children
First posted: 2009-11-24
Enrollment: 56
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of a long-term care facility for children with disabilities who have severe to profound CP and are non-ambulatory.

Brief summary: In 2003, observational growth and bone density data was obtained on children with cerebral palsy (CP) living at Hattie Larlham as part of a study comparing growth with an existing database of children with CP who live at home. The original residents included in that study are now of adult age. Due to the lack of longitudinal bone density measurements in facility-based adults with severe CP, the investigators' objective is to obtain 6-year follow-up data from the residents enrolled in the original study.


Eligibility criteria: Inclusion Criteria:

* Resident of Hattie Larlham Center for Children with Disabilities (HLCCD)
* Previously enrolled in the Growth in a Facility-Based Population of Children with Cerebral Palsy study in 2003

Exclusion Criteria:

* Resident of HLCCD who was not enrolled in the Growth in a Facility-Based Population of Children with Cerebral Palsy study

Primary outcomes:
measure: Dual Energy X-ray Absorptiometry (DEXA) scan results
timeFrame: 6 years from original DEXA scan
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Akron Children's Hospital
name: Martha Blackford, PharmD
role: STUDY_CHAIR
affiliation: Akron Children's Hospital
name: Michael Reed, PharmD
role: STUDY_CHAIR
affiliation: University of North Carolina
name: Richard Henderson, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06553222: Minimally Invasive Non-surgical Therapy With or Without Injectable Bone Putty
Official title: Minimally Invasive Non-surgical Therapy With or Without Injectable Bone Putty in Treating Intra-bony Periodontal Defects (Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Periodontal Bone Defects
Keywords: periodontal bone defect -bone putty -infrabony defect
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-08-14
Enrollment: 30
Sex: ALL
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 parallel groups study group - The interventional group where minimally invasive debridement flap and a putty bone graft is tested and the Control group - where minimally invasive debridement flap is performed without graft
Primary purpose: TREATMENT

Brief summary: • All periodontitis patients with infra bony pockets to be included in this study will diagnosed as having stage III periodontitis with probing pocket depth (PPD) ≥ 6 mm, and clinical attachment loss (CAL) ≥ 5mm will be treated by minimally invasive non-surgical therapy or by injectable bone putty

Detailed description: The present study will be designed as a randomized controlled clinical and radiographic. The study will be carried out on stage III grade (B) periodontitis patients with intra-bony defects. Those patients will be selected from the outpatient clinics of the Department of Oral Medicine and Periodontology, Faculty of Dental Medicine, Al-Azhar University, Assiut branch.

The study has bee approved by the ethical committee, Faculty of Dental medicine, Al-Azhar University, Assiut branch.

2. All patients will be fully informed about the study's nature and the possible risks of the study procedures; they sign the consent form before the work.

Eligibility criteria: Inclusion Criteria:

* • All periodontitis patients to be included in this study should be diagnosed as having stage III periodontitis with probing pocket depth (PPD) ≥ 6 mm, and clinical attachment loss (CAL) ≥ 5mm.

  * 2- or 3-wall intra-bony interproximal defect with depth ≥3 mm, a width of ≥3 mm at its most coronal part and 45-55-degree angulation will be selected in order to reduce defect variability
  * All patients will be free from any systemic diseases according to the American Dental Academy general guidelines for referring dental patients to specialists and other care settings.

Exclusion Criteria:

• Any patients with any systemic condition that contraindicate any surgical intervention

Primary outcomes:
measure: Primary outcome
timeFrame: measured at 6 and 12 months postoperative
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06650722: Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun Hospital
Official title: Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status and Their Relationship to Vaccination at Melun Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vaccinia
Lead sponsor: Groupe Hospitalier Sud Ile-de-France
Sponsor class: OTHER
First posted: 2024-10-21
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Anyone working at GHSIF and has accepted to participate to the study

Brief summary: The goal of this observational study is to learn about the rate the of knowledge of own vaccination status among healthcare workers working at Groupe Hospitalier Sud Ile de France. The main question it aims to answer are : knowledge of own vaccination status is less than 50% among healthcare workers working at Groupe Hospitalier Sud Ile de France and the assessment of the relationship between healthcare workers of Groupe Hospitalier Sud Ile de France and vaccination in general.

Detailed description: Healthcare professionals in France are subject to a number of vaccination obligations, and following successive anti-SARS-CoV2 vaccination campaigns, these obligations are under discussion. Even healthcare professionals are reluctant to be vaccinated , particularly in view of annual vaccination rates against seasonal influenza: 22% were vaccinated against seasonal influenza in 2022, and 25.9% knew their general vaccination status.

As part of the national "European Vaccination Week" event organized by the French Ministry of Health and Prevention, we propose a questionnaire designed for hospital healthcare workers to assess their knowledge of their own vaccination status, and evaluate their attitude with vaccination.

The link to the questionnaire will be forwarded to staff e-mail addresses, and it will be administered on a one-off basis. At least 100 professionals will be surveyed. Each participant is expected to complete the questionnaire in 10 minutes, and the total duration of the research is one week.

Eligibility criteria: Inclusion Criteria:

* Anyone working at GHSIF

Exclusion Criteria:

* Any person refusing to participate

Primary outcomes:
measure: Evaluation of the rate of knowledge of own vaccination status
timeFrame: inclusion visite
Secondary outcomes:
measure: Correlation between healthcare workers and vaccination
timeFrame: inclusion visite
Other outcomes:
Locations:
city: Melun
country: France
facility: Groupe Hospitalier Sud Ile de France
state: Seine Et Marne
Study officials:
References:
Clinical trial NCT03881722: Effect of Magnesium Alginate in Infants With Gastroesophageal Reflux.
Official title: Effect of Magnesium Alginate in Infants With Gastroesophageal Reflux.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gastro Esophageal Reflux
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2019-03-19
Enrollment: 89
Sex: ALL
Minimum age (years): 3
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized controlled cross-over trial
Primary purpose: TREATMENT

Brief summary: Recurrent regurgitation stress the infants and their parents and often results in an inappropirate use of PPI prescription in infancy. The aim of this study is to evaluate the efficacy of Mg alginate in infants with symptoms of gastroesophageal reflux.


Eligibility criteria: Inclusion Criteria:

* symptoms suggestive of GER, evaluated through a validated questionnaire (Infant Gastroesophageal Reflux Questionnaire Revised: I-GERQ-R \> 16)
* informed consent signed

Exclusion Criteria:

* congenital or chronic diseases
* use of anti acid drugs

Primary outcomes:
measure: Infant Gastro-Esophageal Reflux Questionnaire Revised
timeFrame: through study completion, an average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bari
country: Italy
facility: Dept Of Obstetrics and Neonatology - Section of Neonatology University of Bari Policlinico Hospital
Study officials:
References: